Semaglutide and kidney disease: reading FLOW

Start with who was studied

FLOW enrolled 3,533 people with type 2 diabetes and chronic kidney disease under specified filtration and urine-albumin criteria. It tested weekly semaglutide against placebo. Median follow-up was 3.4 years, with early stopping after a planned analysis. The primary outcome occurred in 331 versus 410 participants; the hazard ratio was 0.76. The result is relevant to a defined higher-risk population, not evidence that every person using semaglutide will gain the same kidney benefit.^[1]

The headline combines several outcomes

The primary composite included kidney failure, a sustained major reduction in kidney filtration, or kidney-related or cardiovascular death. Calling the result “24% less kidney failure” would narrow that combined endpoint incorrectly. A composite is a way to count specified events together; each component remains clinically different. When someone shares a percentage, ask for the full outcome definition before deciding what the percentage means.^[1]

A numerical check prevents overstatement

Using the group sizes, 331 divided by 1,767 is about 18.7%, and 410 divided by 1,766 is about 23.2%. The simple difference is approximately 4.5 percentage points over the observed study follow-up. Those rough proportions are not the same calculation as the reported hazard ratio, which incorporates event timing. Do not subtract 24 points from your own estimated risk. To apply a result personally, a clinician needs your baseline risk and the relevance of the trial population. For more on relative and absolute effects, see how to read GLP-1 research.

Understand the two kidney measurements

NIDDK describes blood-based GFR assessment and urine albumin testing as complementary ways to detect and monitor kidney disease. One concerns filtering function; the other looks for protein leakage. Asking for both results and their dates is more informative than writing “kidney labs normal” on a comparison sheet. A single number without its clinical history is not a complete assessment.^[2]

Make coordination part of the provider decision

If considering a separate weight-management service, ask how it will coordinate with the clinician already managing diabetes or kidney disease. Who reviews laboratory results? Who reconciles other prescriptions? Who responds when illness affects eating or drinking? Record the answers before enrolling. A generic promise of messaging does not answer who owns a kidney-monitoring plan. These service questions are especially useful when the clinical decision has already been made but care will span more than one organization. Use the telehealth appointment checklist to organize records and questions.

The kidney indication has its own wording

The January 2025 FDA Ozempic label includes reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. The product and population are both explicit. A prescription marketed simply as “semaglutide for weight loss” does not answer whether that exact indication and approved product are involved. Ask the prescriber to identify the indication in the care plan rather than infer it from the ingredient.^[3]

What the trial does not settle for you

FLOW is a reason to discuss a specific evidence base, not a reason to alter an existing regimen yourself. It does not establish that a higher marketed weight-loss dose provides a larger kidney benefit, or that an unstudied preparation is equivalent. Ask the care team to name the goal, the product, the monitoring schedule and the criteria for reassessment. Keep cost and access on a separate line so a low advertised membership price does not stand in for a coordinated treatment plan.

Continue your research

Sources & scope

Sources checked October 13, 2026. This guide explains published information and consumer research questions; it is not a clinical evaluation.

Prices and terms can change. Confirm your specific offer directly with the provider.